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A B S T R A C T

Background: Heterogeneity in Acute Respiratory Distress Syndrome (ARDS), as a consequence of its non-speciﬁc deﬁnition, has led to a multitude of negative randomised controlled trials (RCTs). Investigators have
sought to identify heterogeneity of treatment effect (HTE) in RCTs using clustering algorithms. We evaluated
the proﬁciency of several commonly-used machine-learning algorithms to identify clusters where HTE may
be detected.
Methods: Five unsupervised: Latent class analysis (LCA), K-means, partition around medoids, hierarchical,
and spectral clustering; and four supervised algorithms: model-based recursive partitioning, Causal Forest
(CF), and X-learner with Random Forest (XL-RF) and Bayesian Additive Regression Trees were individually
applied to three prior ARDS RCTs. Clinical data and research protein biomarkers were used as partitioning
variables, with the latter excluded for secondary analyses. For a clustering schema, HTE was evaluated based
on the interaction term of treatment group and cluster with day-90 mortality as the dependent variable.
Findings: No single algorithm identiﬁed clusters with signiﬁcant HTE in all three trials. LCA, XL-RF, and CF
identiﬁed HTE most frequently (2/3 RCTs). Important partitioning variables in the unsupervised approaches
were consistent across algorithms and RCTs. In supervised models, important partitioning variables varied
between algorithms and across RCTs. In algorithms where clusters demonstrated HTE in the same trial,
patients frequently interchanged clusters from treatment-beneﬁt to treatment-harm clusters across algorithms. LCA aside, results from all other algorithms were subject to signiﬁcant alteration in cluster composition and HTE with random seed change. Removing research biomarkers as partitioning variables greatly
reduced the chances of detecting HTE across all algorithms.
Interpretation: Machine-learning algorithms were inconsistent in their abilities to identify clusters with signiﬁcant HTE. Protein biomarkers were essential in identifying clusters with HTE. Investigations using
machine-learning approaches to identify clusters to seek HTE require cautious interpretation.
Funding: NIGMS R35 GM142992 (PS), NHLBI R35 HL140026 (CSC); NIGMS R01 GM123193, Department of
Defense W81XWH-21-1-0009, NIA R21 AG068720, NIDA R01 DA051464 (MMC)
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)

1. Introduction
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Randomised controlled trials (RCTs) in the traditional paradigm of
evidence-based medicine assume uniform treatment responses
among all individuals. It is clear, however, that this assumption is
invalid, and becomes more so with increasing heterogeneity in the
study population[1,2]. In critical care, where therapies are frequently
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Research in context
Evidence before this study
Heterogeneity subsumed within clinical critical care syndromes, such as acute respiratory distress syndrome (ARDS),
has led to a plethora of “negative” clinical trials. To circumnavigate this heterogeneity, investigators are increasingly seeking
heterogeneity of treatment effect (HTE) in novel phenotypes/
subgroups, with several studies describing approaches to clustering using a multitude of clustering algorithms and data
types. The best approach used for identifying clusters where
HTE is detectable in secondary analysis of clinical trials, and
their comparative beneﬁts and limitations, is not known.

supervised ML algorithms to determine characteristics associated
with HTE [14,15]. The optimal approach to ﬁnding clusters where
HTE is observable, however, remains unknown.
The main objective of this exploratory study was to ascertain the
optimal ML algorithm to consistently identify clusters with HTE. Frequently, approaches that combine protein biomarker data with clinical data are used as partitioning variables for subgroup discovery [8].
The importance of protein biomarkers in identifying clusters where
HTE is observed remains uncertain. A secondary objective, therefore,
was to test whether the detection of HTE was predicated on the inclusion of protein biomarkers as partitioning-variables.
2. Methods
2.1. Overview

Added value of this study
In this study, we present secondary analyses of three randomised controlled trials (RCTs) of ARDS where we compare nine
clustering algorithms (ﬁve unsupervised and four supervised)
to seek HTE in the identiﬁed subgroups. We used a composite
of clinical data and protein biomarkers as partitioning variables.
Latent class analysis (LCA), causal forest and x-learner with random forest identiﬁed HTE in 2/3 of the trials. No single algorithm consistently identiﬁed clusters with HTE. LCA aside, most
algorithms were highly susceptible to random seed changes
leading to alteration of cluster composition and HTE detection.
Protein biomarkers were essential partitioning variables for
successful detection of HTE in the identiﬁed clusters.
Implications of all available evidence
Taken together with the wider literature, our ﬁndings reinforce
the feasibility of detecting HTE in subgroups identiﬁed using
machine learning algorithms. The inconsistencies observed
with seed changes in some of the machine learning algorithms
warrants cautious interpretation of such ﬁndings and mandates
their prospective validation. It is highly probable that no single
algorithm will work in all RCTs and future studies should focus
on matching algorithms that are best suited to speciﬁc data
structures and trial designs.

tested in non-speciﬁc clinical syndromes with broad diagnostic criteria, such as sepsis and acute respiratory distress syndrome (ARDS),
numerous trials have failed to deliver successful therapies [3,4]. The
central premise of precision or personalised medicine is to challenge
this paradigm and focus on delivering the right therapies to the right
patient by embracing the concept of heterogeneity of treatment
effect (HTE). HTE is deﬁned as a non-random, explainable variability
in the direction and magnitude of treatment effect [5]. Conceptually,
subgroup analyses in RCTs are the most common approach to evaluating HTE. However, performing multiple subgroup analyses in RCTs
can result in false discoveries [6,7]. A more predictive, unbiased, and
multivariable approach to HTE analyses has been proposed, as it
avoids the use of single variables with arbitrary cut-offs to determine
subgroups [8].
Increasingly, research groups are using machine learning (ML)
approaches to identify subgroup within critical care syndromes with
the hope of identifying HTE. For example, in ARDS, using latent class
analysis (LCA), two subphenotypes of ARDS, with divergent biological
features, clinical characteristics and outcomes, have been consistently described across ﬁve RCTs [9,12]. In three of these RCTs, the
phenotypes showed differential responses to randomised interventions. In sepsis, using k-means clustering, investigators have identiﬁed subgroups that showed HTE [13]. Others have proposed using

The overview of the analysis plan is summarised in Fig. 1. Brieﬂy,
the performance of each of the nine clustering algorithm was evaluated independently in secondary analyses of three prior ARDS RCTs.
Baseline variables pertaining to demographics, vital signs, ventilatory
metrics, clinical laboratory measurements, and research protein biomarkers served as predictors for each algorithm (Table S1). For each
algorithm, once patients were classiﬁed into clusters, HTE for 90-day
mortality was sought, and variable importance for cluster classiﬁcation was estimated. For secondary analyses, we repeated the above
analyses by 1) generating permutations of random seed initiation for
relevant algorithms to assess their stability; 2) excluding the protein
biomarkers as predictor variables.
2.2. Study Population
Data from three ARDS RCTs conducted by the National Heart, Lung
and Blood Institute’s ARDS-Network were used. Permission to conduct these analyses was provided by BioLINCC. ALVEOLI (n=549)
tested the efﬁcacy of high positive end-expiratory pressure (PEEP)
compared to usual care/lower PEEP [16]. FACTT (n=1000) tested the
efﬁcacy of conservative versus liberal ﬂuid management strategies
[17]. SAILS (n=745) tested the efﬁcacy of rosuvastatin versus placebo
[18]. Speciﬁcally, these three trials were selected because the clinical
data and biomarker availability, timing of recruitment, and inclusion
criteria were relatively uniform across all three RCTs (Table S2). The
use of these three RCTs would enable algorithmic performance evaluation in the same clinical syndrome and independent of variances in
partitioning variables. In SAILS, in addition to ARDS diagnosis, the
inclusion criteria mandated that subjects had a known/suspected
infection and met systemic inﬂammatory response syndrome criteria.
Partitioning variables in the clustering algorithms were collected
prior to randomisation. Biospecimens for protein biomarkers were
collected at enrolment. Assay procedures are described in prior publications [9,11,12].
2.3. Clustering algorithms
The clustering algorithms selected for evaluation were either
those commonly described in the medical literature or prominent in
the data science literature [19]. The algorithms used for unsupervised
clustering were categorised as 1) distance-based: K-means, partitioning around medoids (PAM), hierarchical clustering (HC), and spectral
clustering (SC); 2) probability-based: latent class analysis (LCA).
These algorithms were implemented agnostic to outcome and treatment group allocation.
All non-normally distributed continuous predictor variables were
log-transformed. For algorithms that required complete data, missing
values were replaced by single imputation with chained equations
(MICE package in R) and the same imputed data was used in all algorithms. A summary of the missing values can be found in Table S3.
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Fig. 1. Overview of the analysis plan and study design. ALVEOLI = Assessment of Low Tidal Volume and Elevated End-Expiratory Pressure to Obviate Lung Injury, FACTT = Fluids
and Catheters Treatment Trial, SAILS = Statins for Acutely Injured Lungs from Sepsis, FIML = Full information maximum likelihood. LCA = Latent class analysis, MOB = model based
recursive partitioning, XL-RF = X-learner with Random Forest (RF); XL-BART = Bayesian Additive Regression Trees (BART). HTE = Heterogeneity of treatment effect.

For unsupervised methods, all continuous variables were z-scaled
prior to being used in the algorithms (mean = 0, standard deviation = +/-1). For distance-based clustering, Euclidean distance was
used to determine clusters.
Two to ﬁve clusters were compared in the unsupervised
approaches. Optimal number of clusters was determined using an
unbiased and automated approach for the distance-based algorithms
called consensus clustering. In consensus clustering, each algorithm
was run 1000-times with various combinations of variables, observations, and multiple random starting locations for each run. The cumulative results for each clustering solution are captured in a consensus
matrix. The distribution of the proportion of ambiguous clustering
(PAC) on the cumulative distribution function plot was used to identify the most stable clustering solution using the ConsensusClusterPlus
package in R. For LCA, the model comprising the optimal number of
classes was selected using the Vuong-Lo-Mendel-Rubin test (primary
selection criteria), Bayesian information criteria (BIC), entropy, and
the size of the smallest class [20]. Each model was run with up to
1000 random starts, and models were only considered for evaluation
if the maximum likelihood ratio replicated in at least 20 starts.
The supervised clustering algorithms were trained directly to predict differential treatment responses using outcome and treatment
group allocation as the dependent variables. The four algorithms
used were: model based recursive partitioning (MOB), Causal Forest
(CF), and X-learner with Random Forest (XL-RF) and Bayesian Additive Regression Trees (XL-BART). For all algorithms, out-of-sample
prediction for individual treatment effect (ITE) was generated per
observation. Patients were classiﬁed into one of two clusters,
based on the whether the ITE coefﬁcient was positive or negative.
Details of all algorithms and procedures used are summarised in
the supplement.
2.4. Statistical analysis
For both the supervised and unsupervised approaches, once the
optimal number of clusters were identiﬁed and observations classiﬁed into clusters, HTE was tested using logistic regression models,
where 90-day mortality served as the dependent variable and the
interaction term of clusters and treatment group was the independent variables. P-values for the interaction term were generated
using the ANOVA likelihood ratio test and a signiﬁcant interaction
term (p<0.05) was deﬁned as success for HTE. Odds ratio for heterogeneity of treatment effect in the clusters was generated for each

algorithm (odds ratio > 1 was associated with harm and < 1 with
beneﬁt). Chi-squared test was used to test differences in outcome
between the identiﬁed clusters.
2.5. Variable importance
To determine the most contributory partitioning variables for
cluster identiﬁcation, for each algorithm, gradient boosted machine
models (XGBoost) were trained to classify the identiﬁed clusters
using the same partitioning-variables as predictors in the model
(Table S1). The gain in accuracy in cluster classiﬁcation with the addition of a variable was computed and cumulatively tallied for each
XGBoost model to obtain the relative importance of each variables
per algorithm.
2.6. Sensitivity analyses
ML algorithms are subject to instability with perturbations in the
random initialisation seed (the starting point from which algorithms
are generated). To test the reproducibility of the algorithms, we
repeated the above analyses with random seed iterations for all
approaches (except LCA, where models were only selected if the
maximum likelihood was reproduced in multiple initiation seeds).
Nine further runs were performed, each with a new random seed for
single imputation and the clustering algorithms. Inter-run similarities
in clusters identiﬁed across the 10 runs were evaluated using the
Adjusted Rand Index (ARI).
Finally, to test the importance of biomarkers for identifying clusters where HTE was observed, we repeated the above analyses by
excluding protein biomarkers as predictors.
All clustering approaches, except LCA, were performed on RStudio
version 1.1.453 using R version 4.0.1. LCA was performed using MPlus
version 8.5.
2.7. Ethics statement
Local institutional review board granted a consent-waiver for the
use of de-identiﬁed trial data for research purposes.
2.8. Role of funders
Funders of the study had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
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Fig. 2. Summary of the primary clustering analyses in the three trials. ALVEOLI = Assessment of Low Tidal Volume and Elevated End-Expiratory Pressure to Obviate Lung Injury
(N = 549), FACTT = Fluids and Catheters Treatment Trial (N = 1000), SAILS = Statins for Acutely Injured Lungs from Sepsis (N = 745). LCA = Latent class analysis, PAM = partitioning
around medoids, HC = Hierarchical clustering, MOB = model based recursive partitioning, CF = Causal forest, XL-RF = X-learner with Random Forest (RF); XL-BART = Bayesian Additive Regression Trees (BART). Panel 2a: Optimal number of clusters and proportions of patients in each clusters per algorithm (The colours are representative of the size of the
clusters). Panel 2b: Top 10 variable importance for each clustering algorithm. sTNFR-1 = Soluble tumour-necrosis factor receptor-1, IL-8 = Interleukin-8, WBC = White blood cell
count, ICAM-1 = Intercellular adhesion molecule-1, VE = Minute ventilation, SP-D = Surfactant protein-D, IL-6 = Interleukin-6, PAI-1 = Plasminogen activator inhibitor-1, HR = Heart
rate, P:F ratio = PaO2/FiO2, White (race), VT = Tidal volume, UO = Urine output, BMI = Body mass index, PEEP = = Positive end-expiratory pressure, vWF = Von Willebrand Factor,
Pplat = Plateau pressure, SBP = Systolic blood pressure, Pmean = Mean airway pressure. Panel 2c: Odds ratio for heterogeneity of treatment effect in clusters for each algorithm
(odds ratio > 1 was associated with harm, p-value represents the signiﬁcance of the coefﬁcient of the interaction term of randomised intervention and clusters in a logistic regression model with mortality at day 90 as the dependent variable; P-values were generated for the interaction term using the ANOVA likelihood ratio test).

3. Results
The baseline characteristics of the three RCTs and the predictor
variables are summarised in Table S1. Among the unsupervised clustering approaches, the number of clusters identiﬁed across the
cohorts were largely consistent across the three trials. LCA and kmeans consistently identiﬁed two clusters, whereas PAM and HC
identiﬁed ﬁve clusters (Fig. 2a). Spectral identiﬁed two classes in
ALVEOLI and SAILS, and ﬁve classes in FACTT. The differences in mortality at day-90 between the identiﬁed clusters for each algorithm in
each trial is summarised in Table 1.
Among the unsupervised methods, pro-inﬂammatory biomarkers,
such as interleukin (IL)-8, IL-6 and soluble tumour-necrosis factor
receptor (sTNFR)-1, were prominently and consistently featured as
important variables (Fig. 2b). In the supervised approaches, however,
no discernible patterns were observable across the three trials. Even
within a trial, the pattern of variable importance differed between
the supervised algorithms.
Signiﬁcant HTE interaction with clusters was observed using LCA
and X-learner RF clusters in ALVEOLI and FACTT (Fig. 2c). Using CF,
signiﬁcant HTE were observed in FACTT and SAILS. Using K-means,
PAM, HC and XL-BART, signiﬁcant HTE interactions were only

observed in one out of the three trials. No signiﬁcant HTE interactions
were observed in clusters identiﬁed by either spectral clustering or
MOB. In clusters where signiﬁcant HTE interactions were observed in
the same trial, there were substantial differences in patient composition of clusters across the algorithms (Fig. S1). For example, in FACTT,
where LCA and XL-BART both identiﬁed two clusters with signiﬁcant
HTE, more than half the patients from the increased-mortality cluster
in XL-BART crossed over to the lower mortality cluster in LCA and
vice versa.
In all trials, with both the supervised and unsupervised algorithms, permutations in random seed initialisation in sequential runs
led to several HTE interaction terms no longer being signiﬁcant
despite the same number of clusters being identiﬁed. In ALVEOLI, in
10 consecutive runs, signiﬁcant HTE interactions were observed only
in 2 of 10 runs in HC, 3 of 10 runs in XL-RF and 1 of 10 runs in MOB
(Fig. S2a). In FACTT, signiﬁcant HTE was more consistently observed
in the supervised approaches (CF and XL-BART; 6 and 4 out of 10
runs respectively) but were inconsistent in the unsupervised
approaches (Figure S2b). In SAILS, the ﬁndings of HTE were consistent in k-means and XL-BART, however, in CF and XL-RF HTE was
observed in only 1 out of 10 runs (Fig. S2c). The mean Adjusted Rand
index, a measure of pairwise similarity, for each trial varied widely in
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Table 1
Mortality at day 90 in the three trials stratiﬁed by the clusters identiﬁed by each algorithm. P-values represent chisquared tests between cluster category and death.
% Died in each Cluster
Trial

Method

ALVEOLI

Unsupervised

Supervised

FACTT

Unsupervised

Supervised

SAILS

Unsupervised

Supervised

LCA
K-means
PAM
HC
Spectral
MOB
CF
XL RF
XL BART
LCA
K-means
PAM
HC
Spectral
MOB
CF
XL RF
XL BART
LCA
K-means
PAM
HC
Spectral
MOB
CF
XL RF
XL BART

Cluster 1

Cluster 2

20.0
23.0
20.3
21.5
22.0
25.0
27.8
27.0
19.4
22.1
24.4
14.2
42.5
18.1
25.0
26.9
26.1
32.4
21.4
24.4
23.9
22.4
26.6
30.4
28.3
29.9
25.1

46.2
43.8
24.0
13.5
43.3
25.0
29.2
27.0
35.2
45.1
41.1
25.1
18.3
30.4
32.6
33.6
33.9
23.1
37.5
34.7
19.6
33.3
40.5
18.5
20.8
19.9
31.7

Cluster 3

Cluster 4

Cluster 5

46.4
30.3

10.2
34.5

43.2
50.7

31.8
20.3
36.1

38.3
29.9
23.0

52.9
28.5
47.4

38.2
44.0

20.9
20.0

43.8
18.6

p-value
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
0.31
0.65
0.99
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
0.01
0.06
0.02
< 0.01
< 0.01
0.01
< 0.01
< 0.01
0.07
< 0.01
0.16
0.01
0.06

ALVEOLI = Assessment of Low Tidal Volume and Elevated End-Expiratory Pressure to Obviate Lung Injury (N = 549),
FACTT = Fluids and Catheters Treatment Trial (N = 1000), SAILS = Statins for Acutely Injured Lungs from Sepsis (N = 745).
LCA = Latent class analysis, PAM = partitioning around medoids, HC = Hierarchical clustering, MOB = model based recursive partitioning, CF = Causal Forest, XL-RF = X-learner with Random Forest (RF); XL-BART = Bayesian Additive Regression
Trees (BART).

each algorithm, and its value was generally low throughout, indicating poor overlap between clusters identiﬁed using the various random seed runs for the same algorithm in the same trial cohort
(Fig. 3).
When the above analyses were repeated with protein biomarkers
excluded, as partitioning variables the optimal number of clusters
across each algorithm mostly remained the same, albeit, the proportion of observations in each cluster were markedly different (Fig. 4a).
Important predictor variables across supervised and unsupervised
approaches were more similar, however, there remained notable heterogeneity across the various algorithms (Fig. 4b). Among all the
clustering algorithms, without protein biomarker variables, signiﬁcant HTE interaction was only observed in clusters derived using LCA
in the FACTT trial (Fig. 4c).

4. Discussion
In this study, we found wide variations between ML algorithms in
their abilities to identify clusters in which signiﬁcant HTE was
observed. Even among algorithms where signiﬁcant HTE was
observed, changing the initiation seed frequently led to the interaction terms no longer being signiﬁcant. Further, in most clustering
algorithms, seed changes also led to heterogeneity in the cluster composition across the different runs. Additionally, as evidenced by the
near ubiquitous lack of signiﬁcant HTE in their absence, research protein biomarkers were critical to identifying clusters with HTE. Taken
together, our ﬁndings suggest the ability to identify clusters with
HTE in RCTs is dependent on the clustering algorithm and partitioning variables used, and no single approach consistently identiﬁed
clusters with HTE. Further, the inherent algorithmic instability of

several approaches mandates caution when interpreting research
based on these algorithms.
The relative parity in success of unsupervised and supervised
approaches in detecting HTE is unexpected. It is worth reiterating
that for unsupervised approaches, outcome data and treatment allocation were excluded from the algorithms. In contrast, supervised
approaches were trained directly to detect HTE, and therefore, we
anticipated these approaches to out-perform unsupervised ones. Traditionally, unsupervised learning approaches are used for discovering
underlying structure in unlabelled data [21,22]. Predominantly, such
approaches have been used for biomarker discovery, however, several recent studies have shown that in secondary analyses of RCTs,
clusters identiﬁed using unsupervised methods can lead to discoveries of differential treatment responses [9,11]. Our ﬁndings suggest
that there may be validity in using unsupervised approaches to identify clusters with HTE, although some algorithms (e.g., LCA) performed better than others.
Another potential reason for the relative underperformance of the
supervised methods in our study was that we coerced coefﬁcients of
individual treatment effect (ITE) into dichotomous subgroups to
make them comparable to the unsupervised clustering algorithms, a
process that is known to cause information loss [23]. Future investigations may need to focus more on maximising ITE, rather than using
more traditional approaches of subgroup / cluster HTE analyses, speciﬁcally when comparing supervised methods to one another.
Two potential mechanism that can lead to the discovery of HTE
have been described, 1) prognostic enrichment: whereby the outcome of interest differs between the identiﬁed clusters; 2) predictive
enrichment: which seeks to identify patients that are most likely to
beneﬁt from a therapy. By deﬁnition, given that the models are
trained to seek treatment responsive groups, supervised approaches
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Fig. 3. Mean adjusted rand index score across the random seed runs for each algorithm in each trial (an adjusted rand index score approaching 1 would represent almost complete agreement between cluster composition in the 10 random seed changes runs, whereas, a score of 0 represents almost no agreement). PAM = partitioning around medoids,
HC = Hierarchical clustering, MOB = model based recursive partitioning, CF = Causal forest, XL-RF = X-learner with Random Forest (RF); XL-BART = Bayesian Additive Regression
Trees (BART).

are focused towards predictive enrichment. The similarity in outcomes between clusters, and differences in the most important variables, for the supervised algorithms between RCTs observed in our
study this. In contrast, the most important variables in the unsupervised approaches that identiﬁed clusters with HTE were largely overlapping across RCTs. Which, coupled with the large differences in
mortality, is highly suggestive of prognostic enrichment. Prognostic
enrichment approaches, while more generalisable across trials, may
be non-speciﬁc to the intervention.
Our ﬁndings were also notable for disparities in the variable
importance and cluster composition between algorithms in the same
trial. This ﬁnding was even notable among clusters where HTE was
identiﬁable in the same trial, suggesting that within populations
there may be several different subgroups of patients where HTE is
identiﬁable or that there are a number of patients where their treatment effects are uncertain. In FACTT, among the unsupervised
approaches, HTE was detectable using LCA and PAM, and clusters
were stratiﬁed using IL-8, IL-6, sTNFR-1, and creatinine. Among the
supervised approaches, HTE was detectable in CF, X-learner RF and
BART, and patient clusters were stratiﬁed predominantly using surfactant protein-D, white cell count, intercellular adhesion molecule-1
and minute ventilation. Coupled with the high crossover of patients
from the treatment-beneﬁt to treatment-harm cluster and vice versa,
our ﬁndings suggest that there may be numerous sub-populations
where HTE may be detectable within the same trial population. Even
when the same computational framework, such as X-learner, was
used, the algorithm used to cluster (RF or BART) had a profound
impact on the composition of the clusters as evidenced by crossover
of patients between clusters identiﬁed using the two approaches.
These ﬁndings further reinforce the necessity to prospectively and
externally validate HTE that has been discovered in secondary

analyses of RCTs and, as such, this has also been emphasised in a
recent multidisciplinary expert panel statement for studies using predictive approaches to seek HTE [24].
The inherent instability of several of the algorithms to random
seed makes interpretation of such analyses challenging. Random
seed perturbations leading to algorithmic instability have been
described in other machine-learning approaches [25,26]. [pre-print]
However, this phenomenon remains underappreciated in the medical literature. Inadvertently, investigators may misinterpret local
maxima as the global maxima (i.e., erroneously accept a suboptimal
solution). In algorithms where seed instability is known to be a factor,
investigators should demonstrate the robustness of their ﬁndings to
seed iterations. To that end, it is noteworthy that in LCA, a probabilistic algorithm for determining classes, where the model parameters
are subject to statistical assumptions and hypothesis testing is feasible [20], cluster instability to seed perturbations was not a factor.
This consistency of subgroup identiﬁcation may partly explain why
LCA was one of the most successful methods at identifying clusters
with HTE.
Alongside seed instability, the algorithmic procedures being concealed in a black box, are some of the greatest barriers to real-life
clinical implementation of many machine learning algorithms. Black
box algorithms generate predictions absent of contemporaneous justiﬁcation. From the standpoint of traditional medical practices, a lack
of understanding of the “how” of the algorithm can be counter-intuitive and a barrier to adopting machine-learning clinical decisionmaking [27]. [pre-print] The ﬁrst steps towards implementation of
black-box algorithms is to establish its superiority to simpler and / or
more intuitive models such as logistic regression or LCA. Next, as
with any other modelling, the consistency and robustness of its prediction must be demonstrated in a prospective setting. Once the
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Fig. 4. Summary of the secondary clustering analyses in the three trials where protein biomarker data were excluded as partitioning variables. ALVEOLI = Assessment of Low
Tidal Volume and Elevated End-Expiratory Pressure to Obviate Lung Injury (N = 549), FACTT = Fluids and Catheters Treatment Trial (N = 1000), SAILS = Statins for Acutely Injured
Lungs from Sepsis (N = 745). LCA = Latent class analysis, PAM = partitioning around medoids, HC = Hierarchical clustering, MOB = model based recursive partitioning, CF = Causal forest, XL-RF = X-learner with Random Forest (RF); XL-BART = Bayesian Additive Regression Trees (BART). Panel 4a: Optimal number of clusters and proportions of patients in each
cluster per algorithm (The colours are representative of the size of the clusters). Panel 4b: Top 10 variable importance for each clustering algorithm. WBC = White blood cell
count, VE = Minute ventilation, HR = Heart rate, P:F ratio = PaO2/FiO2, White (race), VT = Tidal volume, UO = Urine output, BMI = Body mass index, PEEP = = Positive end-expiratory
pressure, Pplat = Plateau pressure, SBP = Systolic blood pressure, Pmean = Mean airway pressure. Panel 4c: Odds ratio for heterogeneity of treatment effect in clusters for each
algorithm (odds ratio > 1 was associated with harm, p-value represents the signiﬁcance of the coefﬁcient of the interaction term of randomised intervention and clusters in a logistic regression model with mortality at day 90 as the dependent variable; P-values were generated for the interaction term using the ANOVA likelihood ratio test).

utility and validity of such black-box models has been established,
efforts need to made towards creating models that accompany concise and clear explanation for the prediction at an individual patient
level. The burgeoning ﬁeld of explainable machine learning endeavours to create such models by either presenting the most important
variables driving the prediction or an interpretable translation of the
model design or both [28]. [pre-print], [29] Based on these factors, it is
incumbent for investigators to determine the plausibility of the
explanation for the generated prediction and to establish validity
from a scientiﬁc / biological standpoint.
Inclusion of research protein biomarkers, such as IL-6, IL-8, sTNFR1 and surfactant protein-D, were crucial in identifying clusters with
HTE. These variables consistently featured among the most important
variables and computationally explains why their absence led to
treatment interactions no longer being observed. It may be that the
biological characteristics in clusters derived using these variables
cannot be captured simply using routinely gathered clinical data or
by the clinical data collected at baseline in the included trials. Therefore, when biomarkers are used for partitioning populations, we
hypothesise that the resultant clusters are more likely to be pathophysiologically divergent, increasing the possibilities of divergent
treatment responses [10]. Our study’s ﬁndings strongly suggest that
inclusion of novel biological data can improve the chances of

discovering clusters with divergent outcomes and treatment
responses in ARDS; how generalisable this ﬁnding is to other heterogenous syndromes remains to be tested.
This study has several strengths. Most notably, we used several
machine learning approaches including those that are most widely
used and many that are cutting edge. Throughout, we have used
objective and automated approaches to selecting the optimal number
of clusters. We also evaluated the models in three independent RCTs,
adding validity to the ﬁndings.
This study also has limitations. Subsumed within our primary
hypothesis was the assumption that HTE is present in all three RCTs.
However, it is probable this may not be the case. For example, in
SAILS, given how infrequently HTE was observed, and that observed
HTE was in the context of largely imbalanced cluster sizes, it is conceivable that “true” HTE is not present in this population, however,
such a discovery was attributed as unsuccessful in our study. To that
end, when translating the ﬁndings of HTE analyses in RCTs, the
ground truth will seldom, if ever, be known. Therefore, caution must
be exercised when designing such studies in order to mitigate bias
associated with overﬁtted models that are speciﬁc to the training
dataset. When reporting ﬁndings of such analyses, measure of
robustness should be incorporated, and agreement between multiple
orthogonal approaches should be considered to verify the ﬁndings in
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instances where there is uncertainty on the validity of the observed
HTE. It is also worth reiterating that, until tested prospectively, the
validity of the observed HTE in secondary analyses, such those presented in this study, remains unproven. Additionally, these results
are secondary analyses of RCTs of a single clinical syndrome. The performance of these algorithms prospectively and beyond ARDS is
unknown. Further, these trials can all be considered as “small” data.
It is unclear whether in analyses of larger RCTs, the observed seed
instability of the algorithms and critical importance of protein biomarkers remain valid. Based on the available data and the presented
analyses, we have not been able to determine which of these algorithms performed best at detecting HTE. It may be that the best algorithm to use may depend on the data structure and size and the
quality of the available predictor variables for use in the models. In
future studies, we hope to develop an investigative pipeline that may
help researchers match their trial data characteristics to the most
appropriate algorithm for detecting HTE.
In conclusion, machine learning algorithms were inconsistent in
their abilities to identify clusters with signiﬁcant HTE in secondary
analyses of RCTs. Several of the clustering algorithms were susceptible to signiﬁcant instability with random seed initiations. This stability of algorithms to seed changes should be factored into future
evaluation of such studies. In these populations, inclusion of research
protein biomarkers as partitioning variables greatly enhanced the
ability of the algorithms to identify clusters with HTE. Further studies
are needed to establish machine learning pipelines that can robustly
and consistently identify either at a subgroup or individual level
those that will beneﬁt from therapies in RCTs.
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